Avita Therapeutics, Inc. Announces Correction of Time for the Adjourned 2020 Annual Stockholder Meeting
November 05 2020 - 7:46AM
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announces today a correction
in the time for the adjourned 2020 Annual Stockholder Meeting
(“Adjourned Annual Meeting”), due to the change in daylight savings
time Pacific Time in the United States, it results in change in
time in Australian Eastern Daylight Time (AEDT) from 7:00 am to
8:00 am on Tuesday, November 10, 2020 and remains unchanged at 1:00
pm Pacific Time on Monday, November 9, 2020.
Therefore, the Adjourned Annual Meeting will be held 8:00 am
(AEDT) on Tuesday, November 10, 2020 and 1:00 pm (Pacific Time) on
Monday, November 9, 2020.
Stockholders who have any questions or require any assistance
with how to complete a proxy or CDI Voting Instruction Form or who
do not have the required materials, may contact Okapi Partners by
telephone (toll-free within North America) at (877) 629-6356 or
(call collect outside North America) at (212) 297-0720 or by email
at info@okapipartners.com.
Authorized for release by the Chief Executive Officer of AVITA
Therapeutics, Inc.
Important Information
This material may be deemed to be solicitation material in
respect of the Annual Meeting to be held on November 9, 2020
(Pacific Time) (being November 10, 2020 (AEDT)). In connection with
the Annual Meeting, the Company filed a definitive proxy statement
with the SEC on September 25, 2020. BEFORE MAKING ANY VOTING
DECISIONS, STOCKHOLDERS AND CDI HOLDERS ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED
WITH THE SEC OR THE AUSTRALIAN SECURITIES EXCHANGE (“ASX”), BECAUSE
THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The
definitive proxy statement was mailed to stockholders and CDI
holders entitled to vote at the Annual Meeting. No changes have
been made to the proposals to be voted on by stockholders at the
Annual Meeting. The Company’s proxy statement and any other
materials filed by the Company with the SEC can be obtained free of
charge at the SEC’s website
at https://www.sec.gov/Archives/edgar/data/1762303/000119312520254171/d37466ddef14a.htm
or on the Company’s website at www.avitamedical.com. The proxy
statement and any other materials filed by the Company with the ASX
can be obtained free of charge at the ASX’s website www.asx.com.au
and also the Company’s website at www.avitamedical.com.
ABOUT AVITA THERAPEUTICS,
INC.AVITA Therapeutics is a regenerative medicine company
with a technology platform positioned to address unmet medical
needs in burns, chronic wounds, and aesthetics indications. AVITA
Therapeutics’ patented and proprietary collection and application
technology provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. The medical
devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION,
an autologous suspension comprised of the patient’s skin cells
necessary to regenerate natural healthy epidermis. This autologous
suspension is then sprayed onto the areas of the patient requiring
treatment.
AVITA Therapeutics’ first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns in patients 18 years and older.
The RECELL System is used to prepare Spray-On Skin™ Cells using a
small amount of a patient’s own skin, providing a new way to treat
severe burns, while significantly reducing the amount of donor skin
required. The RECELL System is designed to be used at the point of
care alone or in combination with autografts depending on the depth
of the burn injury. Compelling data from randomized, controlled
clinical trials conducted at major U.S. burn centers and real-world
use in more than 8,000 patients globally, reinforce that the RECELL
System is a significant advancement over the current standard of
care for burn patients and offers benefits in clinical outcomes and
cost savings. Healthcare professionals should read the INSTRUCTIONS
FOR USE - RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings and precautions.
In international markets, our products are marketed under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, chronic wounds and aesthetics. The
RECELL System is TGA-registered in Australia and received CE-mark
approval in Europe.To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTSThis letter includes forward-looking statements.
These forward-looking statements generally can be identified by the
use of words such as “anticipate,” “expect,” “intend,” “could,”
“may,” “will,” “believe,” “estimate,” “look forward,” “forecast,”
“goal,” “target,” “project,” “continue,” “outlook,” “guidance,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this letter include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward- looking statement contained in
this letter is subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statement. Applicable risks and uncertainties include,
among others, the timing of regulatory approvals of our products;
physician acceptance, endorsement, and use of our products; failure
to achieve the anticipated benefits from approval of our products;
the effect of regulatory actions; product liability claims; risks
associated with international operations and expansion; and other
business effects, including the effects of industry, economic or
political conditions outside of the company’s control. Investors
should not place considerable reliance on the forward-looking
statements contained in this letter. Investors are encouraged to
read our publicly available filings for a discussion of these and
other risks and uncertainties. The forward-looking statements in
this letter speak only as of the date of this release, and we
undertake no obligation to update or revise any of these
statements.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy
CurranPhone +1 615 414 8668christycurran@sambrown.comO.U.S
MediaMonsoon CommunicationsRudi
MichelsonPhone +61 (0)3 9620 3333Mobile +61 (0)411 402
737rudim@monsoon.com.au |
InvestorsWestwicke
PartnersCaroline CornerPhone +1 415 202
5678caroline.corner@westwicke.comAVITA
Therapeutics, Inc.David McIntyreChief Financial
OfficerPhone +1 661 367 9178dmcintyre@avitamedical.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024